194225-79-1Relevant academic research and scientific papers
Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh] isoquinolinone derivatives
Shahabi, Manochehr,Schirmer, Eva,Shanab, Karem,Leepasert, Theerachart,Ruzicka, Jana,Holzer, Wolfgang,Spreitzer, Helmut,Aicher, Babette,Schmidt, Peter,Blumenstein, Lars,Müller, Gilbert,Günther, Eckhard
, p. 1846 - 1852 (2013/04/10)
A series of indazolo[4,3-gh]isoquinolinones derivatives have been synthesized to decrease cardiotoxic side effects in comparison to Mitoxantrone. The antiproliferative effects of different side chains were investigated and tested on at least four different cell lines of cervix, ovarian, CNS, NSCLC (non-small-cell lung cancer) and colon carcinoma. In addition to antiproliferative activities, influence on cell cycle and intercalation behavior have been tested.
BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
-
Page 172, (2010/02/08)
Provided are novel compounds having an inhibitory activity against production or secretion of β-amyloid protein. They embrace compounds represented by the following formula (1): and capable of being replaced with a variety of substituents; and salts thereof, and solvates of any one of them.
Synthesis and activity of 6-substituted purine linker amino acid immunostimulants
Zacharie, Boulos,Gagnon, Lyne,Attardo, Giorgio,Connolly, Timothy P.,St-Denis, Yves,Penney, Christopher L.
, p. 2883 - 2894 (2007/10/03)
A series of 6-substituted purinyl alkoxycarbonyl amino acids were synthesized and evaluated for their ability to stimulate cytotoxic T lymphocytes (CTLs) and the mixed lymphocyte reaction (MLR). A few of these compounds, in particular [[5-[6-(N,V-dimethylamino)purin-9- yl]pentoxy]carbonyl]D-arginine (BCH-1393, 4a), displayed an in vitro stimulation of CTLs comparable to interleukin 2 (IL 2). BCH-1393 increased the CTL response between 10-9 M and 10-5 M. Further, this potent in vitroactivity was reflected as a significant increase in CTL cell number in vivo. However, immunophenotyping of some of the other equipotent compounds did not reveal a parallel relative increase in CTLs in vivo. It was difficult to formulate a rigorous structure-activity relationship based on in vitro CTL activity. Nevertheless, the activity was dependent upon the nature of the 6- substituent on the purine, the type and stereochemistry of the amino acid, and the distance and spatial freedom between the purine and amino acid as defined by the length and rigidity of the linker. These compounds were generally nontoxic, as exemplified by BCH-1393. BCH-1393 is a promising immunostimulant which may be targeted for those disease states which require an increased CTL or TH1 type response.
